Ophthalmic Clinical Trials Market Size, Share, Growth & Trends Report by 2034

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Ophthalmic Clinical Trials Market Size Analysis

Global Ophthalmic Clinical Trials Market Introduction
By Phase
1. Introduction
  1. Phase By Value
2. Discovery Phase
  1. By Value
3. Preclinical Phase
  1. By Value
4. Clinical Phase
  1. By Value
  2. Phase I
    1. Phase I By Value
  3. Phase II
    1. Phase II By Value
  4. Phase III
    1. Phase III By Value
  5. Phase IV
    1. Phase IV By Value
By Therapeutic Modality
1. Introduction
  1. Therapeutic Modality By Value
2. Drugs
  1. By Value
  2. Small molecules
    1. Small molecules By Value
  3. Biologics
    1. Biologics By Value
  4. Cell & Gene Therapies
    1. Cell & Gene Therapies By Value
3. Devices
  1. By Value
  2. Surgical & Diagnostics Devices
    1. Surgical & Diagnostics Devices By Value
  3. Vision care Devices
    1. Vision care Devices By Value
4. Others
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Glaucoma
  1. By Value
3. Macular Degeneration
  1. By Value
4. Dry Eye Disease
  1. By Value
5. Cataract & refractive
  1. By Value
6. Uveitis
  1. By Value
7. Retinopathy
  1. By Value
8. Others
  1. By Value
By Sponsor Type
1. Introduction
  1. Sponsor Type By Value
2. Pharmaceutical & Biopharma Companies
  1. By Value
3. Medical Device Companies
  1. By Value
4. Others
  1. By Value

North America Market Analysis

Introduction
By Phase
1. Introduction
  1. Phase By Value
2. Discovery Phase
  1. By Value
3. Preclinical Phase
  1. By Value
4. Clinical Phase
  1. By Value
  2. Phase I
    1. Phase I By Value
  3. Phase II
    1. Phase II By Value
  4. Phase III
    1. Phase III By Value
  5. Phase IV
    1. Phase IV By Value
By Therapeutic Modality
1. Introduction
  1. Therapeutic Modality By Value
2. Drugs
  1. By Value
  2. Small molecules
    1. Small molecules By Value
  3. Biologics
    1. Biologics By Value
  4. Cell & Gene Therapies
    1. Cell & Gene Therapies By Value
3. Devices
  1. By Value
  2. Surgical & Diagnostics Devices
    1. Surgical & Diagnostics Devices By Value
  3. Vision care Devices
    1. Vision care Devices By Value
4. Others
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Glaucoma
  1. By Value
3. Macular Degeneration
  1. By Value
4. Dry Eye Disease
  1. By Value
5. Cataract & refractive
  1. By Value
6. Uveitis
  1. By Value
7. Retinopathy
  1. By Value
8. Others
  1. By Value
By Sponsor Type
1. Introduction
  1. Sponsor Type By Value
2. Pharmaceutical & Biopharma Companies
  1. By Value
3. Medical Device Companies
  1. By Value
4. Others
  1. By Value
U.S.
1. By Phase
  1. Introduction
    1. Phase By Value
  2. Discovery Phase
    1. By Value
  3. Preclinical Phase
    1. By Value
  4. Clinical Phase
    1. By Value
    2. Phase I
      1. Phase I By Value
    3. Phase II
      1. Phase II By Value
    4. Phase III
      1. Phase III By Value
    5. Phase IV
      1. Phase IV By Value
2. By Therapeutic Modality
  1. Introduction
    1. Therapeutic Modality By Value
  2. Drugs
    1. By Value
    2. Small molecules
      1. Small molecules By Value
    3. Biologics
      1. Biologics By Value
    4. Cell & Gene Therapies
      1. Cell & Gene Therapies By Value
  3. Devices
    1. By Value
    2. Surgical & Diagnostics Devices
      1. Surgical & Diagnostics Devices By Value
    3. Vision care Devices
      1. Vision care Devices By Value
  4. Others
    1. By Value
3. By Indication
  1. Introduction
    1. Indication By Value
  2. Glaucoma
    1. By Value
  3. Macular Degeneration
    1. By Value
  4. Dry Eye Disease
    1. By Value
  5. Cataract & refractive
    1. By Value
  6. Uveitis
    1. By Value
  7. Retinopathy
    1. By Value
  8. Others
    1. By Value
4. By Sponsor Type
  1. Introduction
    1. Sponsor Type By Value
  2. Pharmaceutical & Biopharma Companies
    1. By Value
  3. Medical Device Companies
    1. By Value
  4. Others
    1. By Value
Canada

Europe Market Analysis

Introduction
By Phase
1. Introduction
  1. Phase By Value
2. Discovery Phase
  1. By Value
3. Preclinical Phase
  1. By Value
4. Clinical Phase
  1. By Value
  2. Phase I
    1. Phase I By Value
  3. Phase II
    1. Phase II By Value
  4. Phase III
    1. Phase III By Value
  5. Phase IV
    1. Phase IV By Value
By Therapeutic Modality
1. Introduction
  1. Therapeutic Modality By Value
2. Drugs
  1. By Value
  2. Small molecules
    1. Small molecules By Value
  3. Biologics
    1. Biologics By Value
  4. Cell & Gene Therapies
    1. Cell & Gene Therapies By Value
3. Devices
  1. By Value
  2. Surgical & Diagnostics Devices
    1. Surgical & Diagnostics Devices By Value
  3. Vision care Devices
    1. Vision care Devices By Value
4. Others
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Glaucoma
  1. By Value
3. Macular Degeneration
  1. By Value
4. Dry Eye Disease
  1. By Value
5. Cataract & refractive
  1. By Value
6. Uveitis
  1. By Value
7. Retinopathy
  1. By Value
8. Others
  1. By Value
By Sponsor Type
1. Introduction
  1. Sponsor Type By Value
2. Pharmaceutical & Biopharma Companies
  1. By Value
3. Medical Device Companies
  1. By Value
4. Others
  1. By Value
U.K.
1. By Phase
  1. Introduction
    1. Phase By Value
  2. Discovery Phase
    1. By Value
  3. Preclinical Phase
    1. By Value
  4. Clinical Phase
    1. By Value
    2. Phase I
      1. Phase I By Value
    3. Phase II
      1. Phase II By Value
    4. Phase III
      1. Phase III By Value
    5. Phase IV
      1. Phase IV By Value
2. By Therapeutic Modality
  1. Introduction
    1. Therapeutic Modality By Value
  2. Drugs
    1. By Value
    2. Small molecules
      1. Small molecules By Value
    3. Biologics
      1. Biologics By Value
    4. Cell & Gene Therapies
      1. Cell & Gene Therapies By Value
  3. Devices
    1. By Value
    2. Surgical & Diagnostics Devices
      1. Surgical & Diagnostics Devices By Value
    3. Vision care Devices
      1. Vision care Devices By Value
  4. Others
    1. By Value
3. By Indication
  1. Introduction
    1. Indication By Value
  2. Glaucoma
    1. By Value
  3. Macular Degeneration
    1. By Value
  4. Dry Eye Disease
    1. By Value
  5. Cataract & refractive
    1. By Value
  6. Uveitis
    1. By Value
  7. Retinopathy
    1. By Value
  8. Others
    1. By Value
4. By Sponsor Type
  1. Introduction
    1. Sponsor Type By Value
  2. Pharmaceutical & Biopharma Companies
    1. By Value
  3. Medical Device Companies
    1. By Value
  4. Others
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Phase
1. Introduction
  1. Phase By Value
2. Discovery Phase
  1. By Value
3. Preclinical Phase
  1. By Value
4. Clinical Phase
  1. By Value
  2. Phase I
    1. Phase I By Value
  3. Phase II
    1. Phase II By Value
  4. Phase III
    1. Phase III By Value
  5. Phase IV
    1. Phase IV By Value
By Therapeutic Modality
1. Introduction
  1. Therapeutic Modality By Value
2. Drugs
  1. By Value
  2. Small molecules
    1. Small molecules By Value
  3. Biologics
    1. Biologics By Value
  4. Cell & Gene Therapies
    1. Cell & Gene Therapies By Value
3. Devices
  1. By Value
  2. Surgical & Diagnostics Devices
    1. Surgical & Diagnostics Devices By Value
  3. Vision care Devices
    1. Vision care Devices By Value
4. Others
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Glaucoma
  1. By Value
3. Macular Degeneration
  1. By Value
4. Dry Eye Disease
  1. By Value
5. Cataract & refractive
  1. By Value
6. Uveitis
  1. By Value
7. Retinopathy
  1. By Value
8. Others
  1. By Value
By Sponsor Type
1. Introduction
  1. Sponsor Type By Value
2. Pharmaceutical & Biopharma Companies
  1. By Value
3. Medical Device Companies
  1. By Value
4. Others
  1. By Value
China
1. By Phase
  1. Introduction
    1. Phase By Value
  2. Discovery Phase
    1. By Value
  3. Preclinical Phase
    1. By Value
  4. Clinical Phase
    1. By Value
    2. Phase I
      1. Phase I By Value
    3. Phase II
      1. Phase II By Value
    4. Phase III
      1. Phase III By Value
    5. Phase IV
      1. Phase IV By Value
2. By Therapeutic Modality
  1. Introduction
    1. Therapeutic Modality By Value
  2. Drugs
    1. By Value
    2. Small molecules
      1. Small molecules By Value
    3. Biologics
      1. Biologics By Value
    4. Cell & Gene Therapies
      1. Cell & Gene Therapies By Value
  3. Devices
    1. By Value
    2. Surgical & Diagnostics Devices
      1. Surgical & Diagnostics Devices By Value
    3. Vision care Devices
      1. Vision care Devices By Value
  4. Others
    1. By Value
3. By Indication
  1. Introduction
    1. Indication By Value
  2. Glaucoma
    1. By Value
  3. Macular Degeneration
    1. By Value
  4. Dry Eye Disease
    1. By Value
  5. Cataract & refractive
    1. By Value
  6. Uveitis
    1. By Value
  7. Retinopathy
    1. By Value
  8. Others
    1. By Value
4. By Sponsor Type
  1. Introduction
    1. Sponsor Type By Value
  2. Pharmaceutical & Biopharma Companies
    1. By Value
  3. Medical Device Companies
    1. By Value
  4. Others
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Phase
1. Introduction
  1. Phase By Value
2. Discovery Phase
  1. By Value
3. Preclinical Phase
  1. By Value
4. Clinical Phase
  1. By Value
  2. Phase I
    1. Phase I By Value
  3. Phase II
    1. Phase II By Value
  4. Phase III
    1. Phase III By Value
  5. Phase IV
    1. Phase IV By Value
By Therapeutic Modality
1. Introduction
  1. Therapeutic Modality By Value
2. Drugs
  1. By Value
  2. Small molecules
    1. Small molecules By Value
  3. Biologics
    1. Biologics By Value
  4. Cell & Gene Therapies
    1. Cell & Gene Therapies By Value
3. Devices
  1. By Value
  2. Surgical & Diagnostics Devices
    1. Surgical & Diagnostics Devices By Value
  3. Vision care Devices
    1. Vision care Devices By Value
4. Others
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Glaucoma
  1. By Value
3. Macular Degeneration
  1. By Value
4. Dry Eye Disease
  1. By Value
5. Cataract & refractive
  1. By Value
6. Uveitis
  1. By Value
7. Retinopathy
  1. By Value
8. Others
  1. By Value
By Sponsor Type
1. Introduction
  1. Sponsor Type By Value
2. Pharmaceutical & Biopharma Companies
  1. By Value
3. Medical Device Companies
  1. By Value
4. Others
  1. By Value
UAE
1. By Phase
  1. Introduction
    1. Phase By Value
  2. Discovery Phase
    1. By Value
  3. Preclinical Phase
    1. By Value
  4. Clinical Phase
    1. By Value
    2. Phase I
      1. Phase I By Value
    3. Phase II
      1. Phase II By Value
    4. Phase III
      1. Phase III By Value
    5. Phase IV
      1. Phase IV By Value
2. By Therapeutic Modality
  1. Introduction
    1. Therapeutic Modality By Value
  2. Drugs
    1. By Value
    2. Small molecules
      1. Small molecules By Value
    3. Biologics
      1. Biologics By Value
    4. Cell & Gene Therapies
      1. Cell & Gene Therapies By Value
  3. Devices
    1. By Value
    2. Surgical & Diagnostics Devices
      1. Surgical & Diagnostics Devices By Value
    3. Vision care Devices
      1. Vision care Devices By Value
  4. Others
    1. By Value
3. By Indication
  1. Introduction
    1. Indication By Value
  2. Glaucoma
    1. By Value
  3. Macular Degeneration
    1. By Value
  4. Dry Eye Disease
    1. By Value
  5. Cataract & refractive
    1. By Value
  6. Uveitis
    1. By Value
  7. Retinopathy
    1. By Value
  8. Others
    1. By Value
4. By Sponsor Type
  1. Introduction
    1. Sponsor Type By Value
  2. Pharmaceutical & Biopharma Companies
    1. By Value
  3. Medical Device Companies
    1. By Value
  4. Others
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Phase
1. Introduction
  1. Phase By Value
2. Discovery Phase
  1. By Value
3. Preclinical Phase
  1. By Value
4. Clinical Phase
  1. By Value
  2. Phase I
    1. Phase I By Value
  3. Phase II
    1. Phase II By Value
  4. Phase III
    1. Phase III By Value
  5. Phase IV
    1. Phase IV By Value
By Therapeutic Modality
1. Introduction
  1. Therapeutic Modality By Value
2. Drugs
  1. By Value
  2. Small molecules
    1. Small molecules By Value
  3. Biologics
    1. Biologics By Value
  4. Cell & Gene Therapies
    1. Cell & Gene Therapies By Value
3. Devices
  1. By Value
  2. Surgical & Diagnostics Devices
    1. Surgical & Diagnostics Devices By Value
  3. Vision care Devices
    1. Vision care Devices By Value
4. Others
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Glaucoma
  1. By Value
3. Macular Degeneration
  1. By Value
4. Dry Eye Disease
  1. By Value
5. Cataract & refractive
  1. By Value
6. Uveitis
  1. By Value
7. Retinopathy
  1. By Value
8. Others
  1. By Value
By Sponsor Type
1. Introduction
  1. Sponsor Type By Value
2. Pharmaceutical & Biopharma Companies
  1. By Value
3. Medical Device Companies
  1. By Value
4. Others
  1. By Value
Brazil
1. By Phase
  1. Introduction
    1. Phase By Value
  2. Discovery Phase
    1. By Value
  3. Preclinical Phase
    1. By Value
  4. Clinical Phase
    1. By Value
    2. Phase I
      1. Phase I By Value
    3. Phase II
      1. Phase II By Value
    4. Phase III
      1. Phase III By Value
    5. Phase IV
      1. Phase IV By Value
2. By Therapeutic Modality
  1. Introduction
    1. Therapeutic Modality By Value
  2. Drugs
    1. By Value
    2. Small molecules
      1. Small molecules By Value
    3. Biologics
      1. Biologics By Value
    4. Cell & Gene Therapies
      1. Cell & Gene Therapies By Value
  3. Devices
    1. By Value
    2. Surgical & Diagnostics Devices
      1. Surgical & Diagnostics Devices By Value
    3. Vision care Devices
      1. Vision care Devices By Value
  4. Others
    1. By Value
3. By Indication
  1. Introduction
    1. Indication By Value
  2. Glaucoma
    1. By Value
  3. Macular Degeneration
    1. By Value
  4. Dry Eye Disease
    1. By Value
  5. Cataract & refractive
    1. By Value
  6. Uveitis
    1. By Value
  7. Retinopathy
    1. By Value
  8. Others
    1. By Value
4. By Sponsor Type
  1. Introduction
    1. Sponsor Type By Value
  2. Pharmaceutical & Biopharma Companies
    1. By Value
  3. Medical Device Companies
    1. By Value
  4. Others
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Ophthalmic Clinical Trials Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

IQVIA
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Apellis Pharmaceuticals
Carl Zeiss Meditec
Charles River Laboratories
Hoffmann-La Roche Ltd
GenSight Biologics
ICON plc
Iris Pharma
Johnson & Johnson Services Inc.
Laboratory Corporation of America Holdings
Medpace
Novartis AG
Novotech
Parexel
ProTrials Research, Inc.
Regeneron Pharmaceuticals
Santen Pharmaceutical
Syneos Health
TFS HealthScience
Others

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment